Lower levels of inhibin A and pro-αC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human chorionic gonadotropin

被引:55
作者
Nevo, O [1 ]
Eldar-Geva, T [1 ]
Kol, S [1 ]
Itskovitz-Eldor, J [1 ]
机构
[1] Rambam Med Ctr, Dept Obstet & Gynecol, IL-31096 Haifa, Israel
关键词
GnRH agonist; GnRH antagonist; inhibin A; pro-alpha C; IVF; luteal phase; OHSS;
D O I
10.1016/S0015-0282(03)00177-8
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To investigate the effect of triggering oocyte maturation with GnRH agonist on corpus luteum function by measuring luteal phase levels of inhibin A and pro-alphaC. Design: Prospective randomized trial. Setting: In vitro fertilization (IVF) program at a university hospital. Patient(s): Infertile women undergoing IVF-ET treatment. Intervention(s): Controlled ovarian hyperstimulation with FSH and GnRH antagonist, triggering of final oocyte maturation with either hCG (n = 8) or GnRH agonist (n = 8), IVF-ET, and collection of blood samples every 2-3 days during the luteal phase. Main Outcome Measure(s): Luteal phase serum levels of inhibin A and pro-alphaC, P, and E-2. Result(s): Levels of inhibin A, pro-aC, estrogen, and P were significantly lower from day 4 to day 14 after triggering final oocyte maturation by GnRH agonist compared with hCG. Maximal luteal serum inhibin A and pro-aC levels were 91.5 +/- 23.6 and 184.1 +/- 23.5 pg/mL in the GnRH agonist-treated women compared with 464.7 +/- 209.1 and 7,351.6 +/- 934.3 pg/mL in women treated with hCG. Conclusion(s): Triggering final oocyte maturation with GnRH agonist instead of hCG in IVF cycles dramatically decreases luteal levels of inhibins, reflecting significant inhibition of the corpus luteum function. This effect may explain, at least in part, the mechanism of ovarian hyperstimulation syndrome prevention by the use of GnRH agonist. (C) 2003 by American Society for Reproductive Medicine.
引用
收藏
页码:1123 / 1128
页数:6
相关论文
共 26 条
[1]   The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetvorelix [J].
Albano, C ;
Grimbizis, G ;
Smitz, J ;
Riethmüller-Winzen, H ;
Reissmann, T ;
Van Steirteghem, A ;
Devroey, P .
FERTILITY AND STERILITY, 1998, 70 (02) :357-359
[2]   Effects of gonadotrophin-releasing hormone agonists on human ovarian steroid secretion in vivo and in vitro -: results of a prospective, randomized in-vitro fertilization study [J].
Dor, J ;
Bider, D ;
Shulman, A ;
Levron, J ;
Shine, S ;
Mashiach, S ;
Rabinovici, J .
HUMAN REPRODUCTION, 2000, 15 (06) :1225-1230
[3]   Relationship between serum inhibin A and B and ovarian follicle development after a daily fixed dose administration of recombinant follicle-stimulating hormone [J].
Eldar-Geva, T ;
Robertson, DM ;
Cahir, N ;
Groome, N ;
Gabbe, MP ;
Maclachlan, V ;
Healy, DL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (02) :607-613
[4]   Peripheral blood concentrations of inhibin B are elevated during gonadotrophin stimulation in patients who later develop ovarian OHSS and inhibin A concentrations are elevated after OHSS onset [J].
Enskog, A ;
Nilsson, L ;
Brännström, M .
HUMAN REPRODUCTION, 2000, 15 (03) :532-538
[5]   Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization [J].
Fauser, BC ;
de Jong, D ;
Olivennes, F ;
Wramsby, H ;
Tay, C ;
Itskovitz-Eldor, J ;
van Hooren, HG .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (02) :709-715
[6]  
Golan A, 1989, Obstet Gynecol Surv, V44, P430, DOI 10.1097/00006254-198906000-00004
[7]   Measurement of circulating inhibin forms during the establishment of pregnancy [J].
Illingworth, PJ ;
Groome, NP ;
Duncan, WC ;
Grant, V ;
Tovanabutra, S ;
Baird, DT ;
McNeilly, AS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (04) :1471-1475
[8]  
ITSKOVITZ J, 1991, FERTIL STERIL, V56, P213
[9]   Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report [J].
Itskovitz-Eldor, J ;
Kol, S ;
Mannaerts, B .
HUMAN REPRODUCTION, 2000, 15 (09) :1965-1968
[10]   USE OF GONADOTROPIN-RELEASING-HORMONE AGONIST TO CAUSE OVULATION AND PREVENT THE OVARIAN HYPERSTIMULATION SYNDROME [J].
ITSKOVITZELDOR, J ;
LEVRON, J ;
KOL, S .
CLINICAL OBSTETRICS AND GYNECOLOGY, 1993, 36 (03) :701-710